Anti-BCL2 [bcl-2/124]

Monoclonal antibody which binds anti-apoptotic regulator BCL2, used to aid in differentiating between various lymphomas and as prognostic biomarker in various cancers.

Contributors

Inventor Institute
Jacqueline Cordell University of Oxford
Cat. #: 151407
Tool sub type: Primary antibody
Unit size: 100 ug
Research Fields: Apoptosis and autophagy;Cancer;Cell signaling and signal transduction;Metabolism
Application: IHC ; WB
Target: Bcl2
Reactivity: Human
Clone: bcl-2/124
Host: Mouse
Class: Monoclonal
Primary citation: Pezzella et al. 1990. Lancet. 336(8729):1510-1. PMID: 1979117
Product description: Monoclonal antibody which binds anti-apoptotic regulator BCL2, used to aid in differentiating between various lymphomas and as prognostic biomarker in various cancers.
Conjugation: Unconjugated
Isotype: IgG1
Immunogen: Synthetic peptide of amino acids 41-54 of human bcl-2 oncoprotein
Immunogen Uniprot ID: P10415
Myeloma used: P3/NS1/1-Ag4.1
Target background: BCL2 is a member of the BCL-2 family of regulatory proteins, involved in apoptosis, which promotes cell survival and inhibits the role of pro-apoptotic proteins such as Bax and Bak. The pro-survival protein BCL2 derives its name from B-cell lymphoma 2. It is the second member of a range of proteins initially described in chromosomal translocations involving chromosomes 14 and 18 in follicular lymphomas. Damage to the Bcl-2 gene has been identified as a possible cause of schizophrenia and autoimmunity, a cause of cancers, including melanoma, breast, prostate, chronic lymphocytic leukaemia, and lung cancer. It also provides resistance to cancer treatments . This antibody was created to see if the BCL2 protein is a specific marker to the 14;18 chromosomal translocation in human follicular lymphoma. Previous studies claimed the BCL2 protein was not found in normal tissue but was present in all lymphomas where this specific translocation was observed. This antibody helped show the immunohistologic demonstration of BCL2 isn't specific for the presence of 14;18 translocation.
Format: Liquid
Concentration: 1 mg/ml
Storage buffer: PBS with 0.02% azide
Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
Shipping conditions: Dry ice
References:

Shimono et al. 2018. Am J Surg Pathol. 42(11):1466-1471. PMID: 30307409.

Nanni et al. 2018. Mol Cell Biol. 38(13):. PMID: 29685904.

Pricartet al. 2017. Medicine (Baltimore). 96(47):e8705. PMID: 29381956.

Chang et al. 2016. J Formos Med Assoc. :. PMID: 27773559.

Ishiguro et al. 2016. Hum Cell. :. PMID: 27613543.

Otali et al. 2016. Biotech Histochem. :1-18. PMID: 27149658.

Cortese et al. 2016. Neurology. :. PMID: 26843560.

Miltiades et al. 2015. Clin Cancer Res. :. PMID: 26700206.

Tajima et al. 2015. Int J Clin Exp Pathol. 8(3):3262-9. PMID: 26045850.

Pankova et al. 2015. Tumour Biol. :. PMID: 26456960.

Miyagi Maeshima et al. 2015. J Clin Exp Hematop. 55(1):7-11. PMID: 26106000.

Huo et al. 2015. Diagn Pathol. 10:80. PMID: 26112006.

Higashi et al. 2015. Leuk Lymphoma. :1-6. PMID: 25860238.

Navratil et al. 1995. J Clin Pathol. 48(1):18-21. PMID: 7706514.

Ashton-Key et al. 1995. Histopathology. 26(1):75-8. PMID: 7713486.

Piris et al. 1994. Br J Cancer. 69(2):337-41. PMID: 8297731.

Leek et al. 1994. Br J Cancer. 69(1):135-9. PMID: 8286195.

de Jong et al. 1994. Cancer Res. 54(1):256-60. PMID: 8261449.

Pezzella et al. 1993. N Engl J Med. 329(10):690-4. PMID: 8393963.

Doussis et al. 1993. Am J Clin Pathol. 99(6):663-7. PMID: 8322700.

Pezzella et al. 1993. Histopathology. 22(1):39-44. PMID: 8436340.

Gaulard et al. 1992. Am J Pathol. 140(5):1089-95. PMID: 1374590.

Pezzella et al. 1992. Br J Cancer. 65(1):87-9. PMID: 1733447.

Pezzella et al. 1990. Lancet. 336(8729):1510-1. PMID: 1979117.

Images

View Gallery

Related Tools for Antibodies

Cat. # Tool Name
151025 Anti-Vascular endothelium [10] Key Info View Tool
151026 Anti-FCGR1 [10.1] mAb Key Info View Tool
151037 Anti-Cdk1 [17 (A17)] Key Info View Tool
151017 Anti-MBP [R29.6] Key Info View Tool
151018 Anti-Mos [R38.1] Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.